ISSN: 2167-7689
Pharmaceutical Regulatory Affairs: Open Access
Open Access
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Useful Links
Recommended Journals
Related Subjects
Regulatory submissions for blood products at Saudi FDA
3rd International Conference on Pharmaceutical Regulatory Affairs
| Ali Mohammed Alsamil |
| ScientificTracks Abstracts: Pharmaceut Reg Affairs |
| DOI: 10.4172/2167-7689.S1.010 |
| Abstract |
| The Saudi FDA is a government administration that regulates food, drug, as well as medical devices, whether they are imported or locally manufactured. The drug sector oversees and controls human and veterinary medicines, and cosmetic products through constructive regulation policies and guidelines. The main purpose is to ensure the safety, quality, efficacy and availability of all medicines including pharmaceutics and biologics. Thereof, biological products or biologics are medicinal products derived from a variety of natural sources such as human or animal tissues, or microbiological origins, they were created with biotechnology and can be manufactured through diversity of biotech based-methods; they are complex in structure and not fully characterized, and mainly composed of sugar, protein, or nucleic acids or a combination of these substances, they may also be living entities. Like pharmaceutical products, biologics intended to prevent or treat diseases and medical conditions, and can be categorized into a wide range of medicinal products including vaccines, blood and blood components, allergenic extracts, immunosera, somatic cells, gene and cellular therapy, human cells and tissues, and biosimilars. However, biological products intended to be marketing in Saudi Arabia must obtain a marketing authorization approval. The approval for biological products can be achieved once the applications meet the requirements. The applications of biological products can be classified based on the purpose of the application, as follows: new registration, variation, and renewal. These applications shall go through multi steps process, which starts with the validation and ends with the final decision of approval of rejection. For that, the drug sector has developed and adopted many guidelines for industry of biological product. My goal is to provide an overview of this process in Saudi Arabia and share my experience with it. |
| Biography |
| Ali Mohammed Alsamil has completed his Master?s of Biomedical laboratory science at the age of 27 years from Quinnipiac University and Bachelor?s of science in biochemistry from King Saud University. He is specialist in blood bank and transfusion services. Currently, he is an assessor of blood products, a senior biomedical laboratory specialist, in the product evaluation and standards setting at drug sector, Saudi FDA. |
 PDF |  HTML |
Relevant Topics
- Advances in Bioavailability
- Advances in pharmaceutical analytical methods
- Adverse Effects
- Air analysis
- Anvisa Bioequivalence
- Anvisa regulatory guidelines
- BA/BE Studies
- Bioequivalence Anticancers
- Bioequivalence Antidiabetics
- Bioequivalence Antidiuretics
- Bioequivalence Antipsychotics
- Bioequivalence Cardiovascular Products
- Bioequivalence Study Design
- Bioequivalence Study Protocols
- Biopharmaceutics
- Biosimilars
- British regulatory guidelines
- Causality Assesment
- Chemical analysis
- Clinical Cancer Trials
- Clinical Drug Trial
- Clinical Pharmacovigilance
- Clinical Trials Pharmacovigilance
- Competitive analysis of drugs
- Drug Monitoring
- Drug Safety Survillance
- Drug analysis
- Drug devices
- Europe Pharmacovigilance
- European Bioequivalence
- Europian regulatory guidelines
- Experimental Drug Trial
- FDA Bioequivalence
- Good Pharmacovigilance Practice
- In vitro Bioequivalence
- Japan Pharmacovigilance
- Japan regulatory guidelines
- Medical Literature
- Medical devices regulations
- Medication Error
- Paid Clinical Trials
- Periodic Safety Update Reports
- Pharma Risk Management
- Pharmaceutical analysis
- Pharmaceutical analytical market
- Pharmaceutical care
- Pharmaceutical companies and regulatory guidelines
- Pharmaceutical ethics
- Pharmaceutical formulation
- Pharmaceutical technology
- Pharmaceutics
- Pharmacovigilance Regulatory Updates
- Pharmacovigilance and Risk Management
- Pharmacovigilance for Alternative Medicine
- Product analysis and marketing
- Quality assurance in pharmaceutical analysis
- Quality assurance in regulatory affairs
- Regulatory Requirements in Bioequivalence
- Regulatory affairs
- Regulatory affairs for clinical trails
- Regulatory compliance
- Regulatory consulting and market analysis
- Regulatory requirements of pharmaceutical products
- Regulatory services and market analysis
- Spectrometry
- UK Pharmacovigilance
- US FDA guidelines
- US Pharmacovigilance
- Validation
- Veterinary Pharmacovigilance
